KLOW Blend 80mg (50mg GHK-CU 10mg TB500 10mg BPC157 10mg KPV)

KLOW Blend 80mg Research Peptide Blend

KLOW Blend 80mg is a fixed-composition research blend containing four peptide-based compounds: GHK-Cu, BPC-157, TB-500 and KPV.

Each vial contains 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500 and 10mg KPV, providing a total of 80mg of lyophilised research material.

Global Peptides supplies KLOW for controlled laboratory and in-vitro applications only, with independent batch testing and UK-based dispatch.

Product Specifications

Product	KLOW Blend
Total quantity	80mg
GHK-Cu	50mg
BPC-157	10mg
TB-500	10mg
KPV	10mg
Form	Lyophilised powder
Testing	Independent third-party batch testing
Packaging	Sealed laboratory vial
Dispatch	United Kingdom
Intended use	Laboratory research only

KLOW Blend Composition

KLOW combines four distinct research compounds in a single fixed-ratio formulation:

GHK-Cu – 50mg

GHK-Cu is the copper complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (GHK). Laboratory research has investigated GHK-Cu in relation to copper-dependent cellular processes, extracellular matrix signalling, cellular remodelling and peptide-copper interactions.

BPC-157 – 10mg

BPC-157 is a synthetic 15-amino-acid peptide used in experimental models investigating cellular signalling, fibroblast activity, angiogenesis-related pathways and tissue-response mechanisms.

TB-500 – 10mg

TB-500 is a synthetic research peptide associated with thymosin beta-4-derived peptide research. Experimental investigation may examine peptide interactions relating to cellular migration, cytoskeletal processes and tissue-response pathways.

KPV – 10mg

KPV (Lys-Pro-Val) is a three-amino-acid peptide corresponding to the C-terminal tripeptide sequence of alpha-melanocyte-stimulating hormone (α-MSH). KPV has been investigated experimentally in cellular signalling and inflammatory-response models.

Research Context

KLOW is of interest in experimental research because it combines four chemically distinct peptide-based compounds within one fixed formulation.

Laboratory studies may investigate multi-pathway cellular signalling, extracellular matrix processes, cell migration, peptide-copper interactions and inflammatory-response pathways within controlled experimental models.

Because KLOW contains all four components at fixed quantities, it may also be used in experimental designs examining a combined formulation compared with individual compounds or other peptide blends.

The presence of multiple compounds in one vial does not itself demonstrate that the components act synergistically. Any interaction or combined effect must be established experimentally within the relevant research model.

These research areas describe controlled laboratory investigation only and do not imply a clinical, medical, diagnostic or therapeutic application.

KLOW vs GLOW Peptide Blend

KLOW and GLOW are related multi-compound research formulations but contain different compositions.

Global Peptides’ GLOW blend combines GHK-Cu, BPC-157 and TB-500, while KLOW contains these three compounds together with an additional 10mg of KPV.

This gives KLOW a four-component formulation consisting of:

• GHK-Cu – 50mg
• BPC-157 – 10mg
• TB-500 – 10mg
• KPV – 10mg

The two blends should therefore be treated as distinct formulations for experimental purposes.

Independent Batch Testing

KLOW batches are submitted for independent analytical testing. Testing results apply specifically to the batch identified on the relevant Certificate of Analysis and should be read alongside the batch information supplied with the product.

Current batch COA available on request.

More information about our analytical testing and quality standards is available on our Quality & Testing page.

Storage and Laboratory Handling

Keep the sealed lyophilised vial in a cool, dry environment protected from heat, moisture and direct light. Handle only in appropriate laboratory conditions and follow suitable laboratory safety procedures.

Because KLOW is a multi-component formulation, batch-specific documentation should take precedence where particular handling or storage conditions are provided.

Additional information is available in our peptide storage guide.

KLOW Blend Frequently Asked Questions

What is KLOW Blend?

KLOW is a four-component research blend containing GHK-Cu, BPC-157, TB-500 and KPV in a single lyophilised vial.

How much peptide is in KLOW 80mg?

Each KLOW vial contains a total of 80mg: 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500 and 10mg KPV.

What compounds are contained in KLOW?

KLOW contains:

• 50mg GHK-Cu
• 10mg BPC-157
• 10mg TB-500
• 10mg KPV

What is the difference between KLOW and GLOW?

Global Peptides’ GLOW formulation contains GHK-Cu, BPC-157 and TB-500. KLOW contains the same three components together with an additional 10mg of KPV, producing a four-component 80mg blend.

What is KPV?

KPV stands for the amino-acid sequence Lys-Pro-Val. It is a tripeptide corresponding to the C-terminal three amino acids of alpha-melanocyte-stimulating hormone (α-MSH) and is investigated in experimental cellular and inflammatory-signalling models.

What is GHK-Cu?

GHK-Cu is a copper complex formed by the naturally occurring tripeptide glycyl-L-histidyl-L-lysine and a copper ion. It is widely investigated in cellular, extracellular-matrix and tissue-remodelling research.

How is KLOW supplied?

KLOW is supplied as 80mg of lyophilised research material in a sealed laboratory vial.

Is independent testing documentation available?

Yes. Independent batch testing documentation is available on request for the applicable KLOW batch.

Where is KLOW dispatched from?

Orders are dispatched domestically from within the United Kingdom.

Is KLOW intended for human use?

No. KLOW supplied by Global Peptides is strictly for laboratory and in-vitro research. It is not supplied as a medicine, cosmetic or consumer product and is not intended for human consumption, veterinary use, diagnosis or treatment.